Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.51 |
| ▸ | BID | P55957 | 3/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.47 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.47 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.47 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.47 |
| ▸ | SAE1 | Q9UBE0 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | EP300 | Q09472 | 1/20 | 0.47 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.47 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.47 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.47 |
| ▸ | THRA | P10827 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYSLTR2 | Q9NS75 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9456266 | 0.98 | LIPG (0.54) | LIPGBIDMCL1BCL2L1BAK1 | |
| SCHEMBL18519295 | 0.98 | LIPG (0.54) | LIPGBIDMCL1BCL2L1BAK1 | |
| SCHEMBL28468212 | 0.98 | LIPG (0.54) | LIPGBIDMCL1BCL2L1BAK1 | |
| SCHEMBL11569404 | 0.98 | LIPG (0.54) | LIPGBIDMCL1BCL2L1BAK1 | |
| SCHEMBL9456049 | 0.98 | LIPG (0.54) | LIPGBIDMCL1BCL2L1BAK1 | |
| SCHEMBL11570752 | 0.98 | LIPG (0.54) | LIPGBIDMCL1BCL2L1BAK1 | |
| SCHEMBL1901916 | 0.95 | FOLH1 (0.46) | LIPGBIDMCL1BCL2L1BAK1 | |
| SCHEMBL1900362 | 0.87 | FOLH1 (0.48) | TSHRTP53CYP3A4MAPK1ALDH1A1 | |
| SCHEMBL617126 | 0.85 | LIPG (0.55) | LIPGBIDMCL1BCL2L1BAK1 | |
| SCHEMBL7652499 | 0.84 | LIPG (0.58) | LIPGBIDMCL1BCL2L1BAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4902826-A | REACTING LITHIUM 2-CHLOROBENZOATE WITH LITHIUM THIOPHENOXIDE OR DERIVATIVE | BAYER AKTIENGESELLSCHAFT (DE) | 1990-02-20 | — | — | US | claimed |
| JP-1070459-A | — | — | None | — | — | JP | disclosed |
| US-8022072-B2 | Azolylmethylidenehydrazine derivative and use thereof | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-2168951-A1 | AZOLYLMETHYLENEHYDRAZINE DERIVATIVE AND USE THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-31 | — | — | EP | disclosed |
| EP-0641343-B1 | 4-MERCAPTOACETYLAMINO-[2] BENZAZEPINONE(3) DERIVATIVES, AND USE AS ENKEPHALINASE INHIBITORS | MERRELL PHARMA INC (US) | 2003-06-25 | — | — | EP | disclosed |
| EP-0641343-A1 | 4-MERCAPTOACETYLAMINO- 2] BENZAZEPINONE(3) DERIVATIVES, AND USE AS ENKEPHALINASE INHIBITORS | MERRELL PHARMACEUTICALS INC. (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1993023397-A1 | 4-MERCAPTOACETYLAMINO-[2] BENZAZEPINONE(3) DERIVATIVES, AND USE AS ENKEPHALINASE INHIBITORS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| US-5238932-A | Mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-08-24 | — | — | US | disclosed |
| US-4902826-A | REACTING LITHIUM 2-CHLOROBENZOATE WITH LITHIUM THIOPHENOXIDE OR DERIVATIVE | BAYER AKTIENGESELLSCHAFT (DE) | 1990-02-20 | — | — | US | disclosed |
| US-4094900-A | Method of preparing aryloxybenzoic and arylthiobenzoic acids | SMITHKLINE CORPORATION (US) | 1978-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190754-A1 | AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF | ARSA, AHR, HRH2 | LIPG 4573/4885BID 3182/4885MCL1 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.